

10585546

(12) International Application Status Report

Received at International Bureau: 08 February 2005 (08.02.2005)

Information valid as of: Not available

(10) Publication number:

WO2005/067952

(43) Publication date:

28 July 2005 (28.07.2005)

(26) Publication language:

English (EN)

(21) Application Number:

PCT/EP2005/000206

(22) Filing Date:

12 January 2005 (12.01.2005)

(25) Filing language:

English (EN)

(31) Priority number(s):

P.364411 (PL)

(31) Priority date(s):

15 January 2004 (15.01.2004)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

A61P 3/04 (2006.01)

(71) Applicants:

BRINGWELL INTERNATIONAL AB [SE/SE]; Hovslagargatan 5A S-111 48 Stockholm (SE) *(for all designated states except US)*

KROTKIEWSKI, Marcin [PL/SE]; Lövmossevägen 1 S-436 39 Askim (SE) *(for US only)*

(72) Inventors:

KROTKIEWSKI, Marcin; Lövmossevägen 1 S-436 39 Askim (SE)

(74) Agent(s):

LAZEWSKI, Marek; Lazewska i Lazewski Myslowicka 15 PL-01-612 Warsaw (PL)

(54) Title (EN): FORMULATION FOR TREATING OBESITY AND ASSOCIATED METABOLIC SYNDROME

(54) Title (FR): FORMULATION DESTINEE AU TRAITEMENT DE L'OBESITE ET DU SYNDROME METABOLIQUE ASSOCIE

(57) Abstract:

(EN): The invention relates to the formulation for treating obesity and associated metabolic syndrome. The formulation is a combination of especially selected vegetable extracts: Green tea extract containing Epigallocatechin galate (EGCG), *Coleus forskholii* extract, *Betula alba* extract and Guarana or Yerba Maté extract. According to clinical *in vivo* and *in vitro* studies use of formulation of the invention is to be treated as verified method of helping treating all known forms of obesity and associated comorbidities. One of the most important advantages of the formulation of the invention apart from the acceleration of weight loss is the prevention of weight regain after the termination of slimming cure.

(FR): L'invention concerne une formulation destinée au traitement de l'obésité et du syndrome métabolique associé. Cette formulation est une association d'extraits végétaux spécialement sélectionnés: extrait de thé vert contenant l'épigallocatechine galate (EGCG), extrait de *Coleus forskholii*, extrait de *Betula alba* et extrait de Guarana ou de Yerba Maté. Selon des études cliniques *in vivo* et *in vitro*, l'utilisation de la formulation de l'invention est à traiter comme méthode vérifiée permettant d'aider au traitement de toutes les formes connues d'obésité et des comorbidités associées. La formulation selon l'invention offre non seulement l'avantage d'une accélération de la perte de poids mais aussi de la prévention d'une reprise pondérale une fois la cure d'amaigrissement terminée.

International search report:

Received at International Bureau: 12 September 2005 (12.09.2005) [EP]

International preliminary examination report:

Chapter II demand received: 07 November 2005 (07.11.2005)

(81) Designated States:

AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

European Patent Office (EPO) : AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

10585546

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

REVISED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 July 2005 (28.07.2005)

PCT

(10) International Publication Number
WO 2005/067952 A1

(51) International Patent Classification⁷: **A61K 35/78**,
A61P 3/04

GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(21) International Application Number:
PCT/EP2005/000206

(22) International Filing Date: 12 January 2005 (12.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P.364411 15 January 2004 (15.01.2004) PL

(71) Applicant (for all designated States except US): **MULTI-
PHARMA 1 GÖTEBORG AB** [SE/SE]; PO Box 9020,
S-400 91 Göteborg (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **KROTKIEWSKI,**
Marcin [PL/SE]; Lövmossevägen 1, S-436 39 Askim
(SE).

(74) Agent: **LAZEWSKI, Marek**; Patent and Trade Mark At-
torneys, Rydygiera 8 Suite 801, PL-01-793 Warsaw (PL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the revised international search
report: 3 November 2005

(15) Information about Correction:
see PCT Gazette No. 44/2005 of 3 November 2005, Sec-
tion II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 2005/067952 A1

(54) Title: FORMULATION FOR TREATING OBESITY AND ASSOCIATED METABOLIC SYNDROME

(57) Abstract: The invention relates to the formulation for treating obesity and associated metabolic syndrome. The formulation is a combination of especially selected vegetable extracts: Green tea extract containing Epigallocatechin galate (EGCG), *Coleus forskholii* extract, *Betula alba* extract and Guarana or Yerba Maté extract. According to clinical *in vivo* and *in vitro* studies use of formulation of the invention is to be treated as verified method of helping treating all known forms of obesity and associated comorbidities. One of the most important advantages of the formulation of the invention apart from the acceleration of weight loss is the prevention of weight regain after the termination of slimming cure.